Skip to main content

Table 1 Clinical and pathological information of study cases

From: Immunohistochemical evaluation of ROCK activation in invasive breast cancer

  Total CIS IC ICM
Age (years) 53 (25, 95) 50 (25, 77) 54 (29, 95) 53 (28, 87)
Gradea 275 56 116 103
 1 26 (9 %) 13 (23 %) 12 (10 %) 1 (1 %)
 2 172 (63 %) 36 (64 %) 74 (64 %) 62 (60 %)
 3 77 (28 %) 7 (13 %) 30 (26 %) 40 (39 %)
ER 266 54 111 101
 Negative 88 (33 %) 7 (13 %) 37 (33 %) 44 (44 %)
 Positive 178 (67 %) 47 (87 %) 74 (67 %) 57 (56 %)
PR 265 54 111 100
 Negative 126 (48 %) 14 (26 %) 55 (50 %) 57 (57 %)
 Positive 139 (52 %) 40 (74 %) 56 (50 %) 43 (43 %)
HER2 264 53 109 102
 Negative 199 (72 %) 45 (85 %) 84 (77 %) 70 (69 %)
 Positive 65 (25 %) 8 (15 %) 25 (23 %) 32 (31 %)
Follow up (months) 108 (1, 262) 97 (1, 213) 132 (9, 262) 86 (1, 257)
  1. Data presented as mean (range) or number (%)
  2. CIS, Carcinoma in situ; IC, Invasive carcinoma; ICM, Invasive carcinoma with metastasis; ER, estrogen receptor; PR, progesterone receptor. aCIS was graded by nuclear grade; IC and ICM were graded by Nottingham histologic score